Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7467972 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL7679543 | 0.73 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL6950463 | 0.72 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL7529385 | 0.72 | MAPK13 (0.48) | GRIN2BTRPV4FAAHCETPF2R | |
| SCHEMBL7468591 | 0.72 | TRPC3 (0.42) | SMN1; SMN2NPC1RAB9ALNPEPGRIN2B | |
| SCHEMBL6173126 | 0.71 | MAPK14 (0.41) | SMN1; SMN2NPC1RAB9AGRIN2BTRPV4 | |
| SCHEMBL6170576 | 0.71 | MAPK14 (0.49) | GRIN2BTRPV4FAAHF2R | |
| SCHEMBL6175245 | 0.71 | MAPK13 (0.49) | SMN1; SMN2NPC1RAB9ALNPEPGRIN2B | |
| SCHEMBL6172304 | 0.71 | MAPK14 (0.49) | SMN1; SMN2NPC1RAB9AGRIN2BTRPV4 | |
| SCHEMBL5753879 | 0.70 | TRPC3 (0.42) | SMN1; SMN2NPC1RAB9AGRIN2BTRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628665-A2 | 3-PHENYL-4-(PYRIMIDIN-2-YL)-6-(PIPERIDIN-4-YL) DERIVATIVES AND RELATED COMPOUNDS AS TNF-ALPHA AND IL-1 INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20040254178-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004094379-A2 | 3-PHENYL-4- (PYRIMIDIN-2-YL) -6- (PIPERIDIN-4-YL) DERIVATIVES AND RELATED COMPOUNDS AS TNF-ALPHA AND IL-1 INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254178-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MAPT, MUSK | SMN1; SMN2 9/4885NPC1 2806/4885RAB9A 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.